Human Growth Hormone Anti-Aging

From pituitary extracts to recombinant hormone

A 2025 clinical review reports that therapeutic use of growth hormone dates to the late 1950s, when it was limited to children with a complete deficiency and was extracted from the pituitary glands of cadavers. In 1985 the first cases of Creutzfeldt-Jakob disease were reported in people who had received the extracted hormone as children, and the review states that more than 50 cases were eventually reported and that cadaver-derived hormone was withdrawn from human use in late 1985. In the mid-1980s recombinant DNA methods allowed production of biosynthetic hormone in large quantities, which the review says widened the range of proposed uses.

The 1990 study that opened the aging question

In 1990 Rudman and colleagues published a study in the New England Journal of Medicine of 21 healthy men aged 61 to 81 whose blood levels of insulin-like growth factor I (IGF-I) were low. Twelve received biosynthetic growth hormone for six months and nine received no treatment. The treated group showed an 8.8 percent increase in lean body mass, a 14.4 percent decrease in adipose tissue mass and a 1.6 percent increase in lumbar vertebral bone density, with no significant change in the untreated group. The authors concluded that reduced growth hormone secretion is responsible in part for loss of lean mass, gain of fat and skin thinning in old age. The abstract does not describe randomization or blinding.

An Endocrine Society scientific statement later described the age-related decline of growth hormone secretion as a recognized feature of aging, while noting that obesity, sleep disruption, fitness and sex steroid levels also relate to growth hormone release. It also noted that animal models with reduced growth hormone signaling live longer, that it is unclear whether this applies to humans, and that the animal work involves lifelong rather than late-life changes.

Elective use in aging and sport

A 2007 systematic review opened by stating that human growth hormone was widely used as an anti-aging therapy even though its use for that purpose was not approved by the United States Food and Drug Administration. A 2008 systematic review stated that growth hormone was reportedly used to enhance athletic performance and that its safety and efficacy for that purpose were poorly understood. The sources reviewed for this page do not trace the history or size of anti-aging clinics or of use among athletes, so no account of either is given here.

Names and the established-use distinction

Human growth hormone, abbreviated HGH or GH, is the hormone made by the pituitary gland; recombinant human growth hormone (rhGH, somatropin) is the manufactured form. Clinical guidelines from the Endocrine Society and the American Association of Clinical Endocrinologists cover diagnosed adult growth hormone deficiency, and a Chinese expert consensus likewise frames its topic as aging related to deficiency. Treatment of diagnosed deficiency, including in children and in conditions such as Turner syndrome, is standard medical care and is not the subject of this page. The phrase anti-aging use here means giving growth hormone to people without a diagnosed deficiency in order to counter aging, change body composition or improve performance.

Because growth hormone is one of several hormones given to older adults, this page relates to the Machipedia page Hormone Replacement Therapy, which covers hormone replacement more broadly and is not repeated here. The Machipedia pages Testosterone Replacement Therapy (TRT), NAD+ IV Therapy, Calorie Restrictive Diet and Intermittent Fasting cover other practices that are discussed in connection with aging; this page does not compare them.

Releasing agents and secretagogues

Two further groups of compounds act on the same axis without being growth hormone itself. Growth hormone-releasing hormone (GHRH) analogues stimulate the pituitary to release its own hormone, and growth hormone secretagogues, which mimic ghrelin, do the same through a different receptor. The World Anti-Doping Agency list names sermorelin, tesamorelin and CJC-1295 among the releasing hormone analogues, and ipamorelin and ibutamoren (MK-677) among the secretagogues. These compounds are also sold in wellness settings under the label peptides, and the Machipedia page Peptide Therapy covers that wider category.

What this page does not describe

This page gives general information only. It does not describe doses, products, schedules, combinations, sourcing or preparation, and none of the sources used here are guides to doing so. The sources reviewed describe growth hormone as given by injection in the trials they summarize, and they describe elective use only in terms of the populations studied and the outcomes measured.

Medical oversight and professional bodies

Professional guidance concerns diagnosed deficiency. The Endocrine Society guideline states that confirming adult growth hormone deficiency usually requires stimulation testing, that dosing should be individualized and that the decision to treat requires careful clinical judgment of benefits and risks for the individual. The 2019 American Association of Clinical Endocrinologists guideline states that establishing a correct diagnosis is essential before replacement is considered, and it also discusses unapproved uses related to sports and aging. These are guidelines for endocrinologists on deficiency, not training standards for elective use, and the sources reviewed do not describe a professional register, credential or training standard specific to anti-aging use of growth hormone.

Aging and body composition

Proponents of anti-aging use draw on the observation that growth hormone secretion declines with age, together with findings such as those of the 1990 study that treatment changed lean mass and fat mass in older men. Clinical reviews describe the hoped-for outcomes as more muscle, less fat, better bone, skin, cognition and vascular function, and lower frailty, and they note that trials of the hormone and of releasing agents in older adults have measured these outcomes.

Performance and recovery

In sport and fitness settings growth hormone is reportedly used to build lean mass and to improve strength and exercise capacity, according to the 2008 systematic review. The same review and a 2023 umbrella review evaluated these claims in healthy young people, and their findings are summarized under Research and Evidence below.

Healthy older adults: the 2007 systematic review

Liu and colleagues searched for randomized trials, through November 2005, of growth hormone in community-dwelling people averaging 50 or older, excluding trials for a specific illness. They found 18 study populations; 220 treated participants completed the studies, with a mean age of 69 and a mean treatment time of 27 weeks. Fat mass decreased by about 2.1 kg and lean body mass increased by about 2.1 kg compared with no treatment, with no significant change in weight. Bone density and most lipid levels did not change.

The authors noted that most studies were small. They concluded that the evidence shows small body composition changes with increased adverse events, and that growth hormone cannot be recommended as an anti-aging therapy.

Athletic performance in healthy young people

A 2008 systematic review of randomized trials in healthy participants aged 13 to 45 included 27 study samples with 303 treated participants who were young, lean and fit. Lean body mass increased by about 2.1 kg, but strength and exercise capacity did not appear to improve, and treated participants more often had edema and fatigue. The authors concluded that claims of improved performance are not supported by the literature, noting that few studies measured athletic performance.

A 2023 umbrella review reached a consistent conclusion for growth hormone: it altered body composition without a strength or performance benefit, with potential risks of edema, fatigue, joint pain and carpal tunnel syndrome. These findings concern people without deficiency and do not apply to diagnosed deficiency.

Secretagogue trials in older adults

The Endocrine Society scientific statement summarizes two randomized, placebo-controlled trials of oral secretagogues in older people. In 65 healthy adults aged 60 to 81, MK-677 for 12 months raised fat-free mass by about 1.1 kg versus a fall on placebo, but visceral fat, total fat mass, strength and physical function were unchanged; side effects included appetite, mild leg edema, muscle pain, small glucose rises and reduced insulin sensitivity. In 395 adults aged 65 to 84 with mild functional limitation, capromorelin was stopped early for missing its effect criteria, although lean mass and a walking test improved; adverse events included fatigue, insomnia and small glucose rises. Development of both compounds was not pursued. No trial of sermorelin or CJC-1295 in healthy older adults appears in the sources reviewed.

What professional bodies state

The Endocrine Society's 2023 statement says no therapy that raises growth hormone secretion or action is approved for anti-aging, and that studies of the hormone and secretagogues failed to show benefits outweighing risks. It adds that other designs might change the balance and calls for longer studies. A 2025 review likewise says it is not advised for anti-aging in healthy older people. A 2025 Chinese expert consensus on aging related to growth hormone deficiency proposes recommendations for deficiency-related aging; its abstract does not extend them to healthy people, and only the abstract was read for this page.

Adverse effects reported in trials

In the 2007 review of healthy older adults, people given growth hormone were significantly more likely to have soft tissue edema, joint pain (arthralgia), carpal tunnel syndrome and gynecomastia, and somewhat more likely to develop diabetes or impaired fasting glucose. A 2025 review that collected trial reports gave wide ranges for such effects, for example fluid retention in 11 to 100 percent of participants, carpal tunnel syndrome in 7 to 50 percent, joint pain in 14 to 77 percent and breast tenderness or enlargement in 7 to 14 percent, while noting that safety reporting in these trials was incomplete. In the 2008 review of young athletes, edema and fatigue were more frequent in treated participants.

Glucose, cancer and mortality

The 2025 review lists as the most worrying long-term concerns raised in the literature an increase in cardiovascular complications, type 2 diabetes and several cancers, and says these require further study. A separate review of manufacturer registries, which concerns people treated for deficiency or short stature and not elective use, found no increased mortality in children or adults, no increased stroke or new malignancy in people without risk factors, a higher risk of second neoplasms mainly after radiation for central nervous system tumors, and a possible increase in type 2 diabetes confined to people with pre-existing risk factors. Its authors advised caution and monitoring in people with risk factors. These registry findings should not be read as showing the same safety profile for healthy people using the hormone electively, and the sources reviewed contain no long-term outcome trials in that group.

Product quality and sport rules

The United States Anti-Doping Agency states that peptide hormones are increasingly found in products sold online, often labeled for research use only, and that the safety of such products has not been established. The sources reviewed do not report laboratory analyses of the contents of such products, so this page cannot state how often they differ from their labels. The World Anti-Doping Agency Prohibited List includes growth hormone, its analogues and fragments, growth hormone-releasing hormone analogues, secretagogues and releasing peptides under category S2, and the agency states these peptide hormones are prohibited in sport at all times.

Suitability and care boundaries

The Endocrine Society and the American Association of Clinical Endocrinologists address growth hormone treatment in the context of diagnosed deficiency, with testing and individual risk-benefit review. Symptoms attributed to aging, such as fatigue, weight gain or low muscle mass, have many medical causes, and this page does not suggest delaying or replacing medical evaluation of them. Anyone with a history of cancer, diabetes or glucose intolerance is among the groups for whom the sources report particular caution in deficiency settings, and a physician should be consulted about individual circumstances.